Robert Cyran and Reynolds Holding discuss Juno Therapeutics' IPO and the prospects for its cancer drug as well as other promising technologies in the booming sector.Video
Reuters Breakingviews is the world's leading source of agenda-setting financial insight. The company was founded in 1999 as Breakingviews.com and was acquired by Thomson Reuters in 2009, becoming Reuters’ brand for financial commentary. Every day, we comment on the big financial stories as they break. Our expert analysis is provided by a global team of 30 correspondents based in New York, Washington, London, Hong Kong, Madrid, Dubai and Mumbai.
For the full commentary and analysis service from breakingviews.com, including regular emails containing the latest views, contact firstname.lastname@example.org.